Clicky

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(688505)

Description: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.


Keywords: Pharmacology Drug Discovery Tumor Clinical Trial Rheumatoid Arthritis Technology Development Lung Cancer Clinical Research Ulcerative Colitis Acne Genetic Engineering Medical Diagnostic Atopic Dermatitis HPV Triple Negative Breast Cancer Paclitaxel Pre Clinical Development Doxorubicin Bio Pharmaceutical Products Medical Diagnostic Products Obeticholic Acid Breast And Gastric Cancers Health Research Pharmaceutical And Medical Devices Brain Gliomas Cervical Diseases Fzj 003 Hepatobiliary And Autoimmune Disease Infantile Hemangioma Oral Solid Preparation Technology Preparation Technology Timolol Maleate Trop2 Bb05 Trop2 Sn38

Home Page: www.fd-zj.com

Zhangjiang Hi-Tech Park
Shanghai, 201210
China
Phone: 86 21 5895 3355


Officers

Name Title
Mr. Hai Bo Wang Co-Founder, Chairman & GM
Mr. Da Jun Zhao Co-Founder, Deputy GM & Exec. Director
Mr. Yong Su Deputy GM & Exec. Director
Mr. Jun Li Co-Founder & Deputy GM
Ms. Xue Yan FCCA, HKICPA, ACCA, CICPA, CIA CFO & Company Sec.
Mr. Xiaolin Yang Deputy Gen. Mang.
Mr. Yi Min Gan Deputy Gen. Mang.
Ms. Dai Qing Yu Quality Director & Employee Representative Supervisor

Exchange: SHG

Country: CN

Currency: Renminbi (¥)

Forward PE: 0
Trailing PE: 78.1818
Price-to-Book MRQ: 4.4818
Price-to-Sales TTM: 6.3467
IPO Date:
Fiscal Year End: December
Full Time Employees: 776
Back to stocks